久量股份(300808.SZ)未被列入廣東省2019年擬認定高新技術企業名單
格隆匯1月23日丨久量股份(300808.SZ)公佈,公司於2016年通過國家高新技術企業認定取得了《高新技術企業證書》,有效期三年(2016年、2017年和2018年)。公司根據相關規定,於2019年進行了高新技術企業的資格重新認定,根據已經公示的廣東省2019年擬認定高新技術企業名單,公司未被列入該公示名單,公司預計2019年度不能享受高新技術企業的企業所得税優惠政策,應按25%的税率繳納企業所得税,公司預計減少淨利潤約754.92萬元。以上數據未經審計,最終會計處理將以會計師事務所年度審計確認後的結果為準。
公司將繼續開展2020年度高新技術企業資格認定的申報工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.